Drug Resistance Assay
The high take rate of subrenal capsule xenografts enables researchers to readily study tumor behavior, growth, progression, metastasis, or acquired drug resistance of a great variety of precancerous and cancerous diseases in vivo. Based on previous studies, many of our PDXs have known drug sensitivity/resistance for various cytotoxic drugs..Status of drug-resistance markers in some of the PDXs have also been investigated, or can be readily screened using tissue microarray or mRNA expression profiles. Acquired drug resistance can be established by treating tumor lines with multiple cycles and selecting drug-resistant subpopulations. The following figures show that some of the ovarian cancer or lung cancer PDXs exhibit various responses to standard chemotherapy.
Figure 1. Drug responses in ovarian Living Tumor Lines
T/C = average treated tumor mass/average control tumor mass
Figure 2. Drug responses in lung Living Tumor Lines
T/C = average treated tumor mass/average control tumor mass
CDDP-cisplatin
VNB-vinorelbine
TXT-docetaxel
• Drug resistance lines are being developed via multiple cycles of standard chemotherapy treatment of selected Living Tumor lines
| Subline origin | Sublines | Bio-characteristics of sublines |
|---|---|---|
| LTL-79 | LTL-79/C13 | 10 cycles of CDDP+VP16 treatment. Tumor is resistant to the drug |
| LTL-117 | LTL-117/C6 | 6 cycles of CDDCP+VNB. Tumor is still response to the drug. |
| LTL-175 | LTL-175/C6 | 6 cycles of carboplatin and paclitaxol treatment. Tumor is still response to the drug. |
| LTL-297B | LTL-297B/C4 | 4 cycles of carboplatin and paclitaxol treatment. Tumor is resistant to the drug. |